News and analysis on global M&A and corporate financing strategies

Finance / United States

Roche Offers US$43.7bn for Genentech

July 2008 | In The News
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.

[
: *
[
: *


If you would like to subscribe to Corporate Financing Week and gain instant access to this article, please click here to subscribe.

If you would like to take a trial to Corporate Financing Week please click on the trial link below.

In a deal that could blow the rest of 2008's pharmaceutical acquisitions out of the water, Swiss drugmaker Roche has offered to buy the remaining shares US biotechnology giant Genentech for US$43.7bn. Roche - which currently owns a majority 55.9% share in the US firm - offered US$89 per share, an 8.8% premium on closing price.